Parkinson's disease : Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study
(2019) In Journal of Neurology, Neurosurgery and Psychiatry 90(2). p.165-170- Abstract
Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment... (More)
Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1-42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ1-42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.
(Less)
- author
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- amyloid-beta, CSF, longitudinal, Parkinson
- in
- Journal of Neurology, Neurosurgery and Psychiatry
- volume
- 90
- issue
- 2
- pages
- 165 - 170
- publisher
- BMJ Publishing Group
- external identifiers
-
- scopus:85053886033
- pmid:30254084
- ISSN
- 0022-3050
- DOI
- 10.1136/jnnp-2018-318956
- language
- English
- LU publication?
- yes
- id
- df04979a-bed6-430e-ba21-b91db31ab4d4
- date added to LUP
- 2018-10-22 13:58:23
- date last changed
- 2024-09-17 05:41:40
@article{df04979a-bed6-430e-ba21-b91db31ab4d4, abstract = {{<p>Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ<sub>1-42</sub> levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ<sub>1-42</sub> levels. Sixty-seven per cent of the patients with low Aβ<sub>1-42</sub> levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ<sub>1-42</sub> levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ<sub>1-42</sub> levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ<sub>1-42</sub> are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.</p>}}, author = {{Lerche, Stefanie and Wurster, Isabel and Röben, Benjamin and Machetanz, Gerrit and Zimmermann, Milan and Bernhard, Felix and Stransky, Elke and Deuschle, Christian and Schulte, Claudia and Hansson, Oskar and Zetterberg, Henrik and Gasser, Thomas and Berg, Daniela and Maetzler, Walter and Brockmann, Kathrin}}, issn = {{0022-3050}}, keywords = {{amyloid-beta; CSF; longitudinal; Parkinson}}, language = {{eng}}, number = {{2}}, pages = {{165--170}}, publisher = {{BMJ Publishing Group}}, series = {{Journal of Neurology, Neurosurgery and Psychiatry}}, title = {{Parkinson's disease : Evolution of cognitive impairment and CSF Aβ<sub>1-42</sub> profiles in a prospective longitudinal study}}, url = {{http://dx.doi.org/10.1136/jnnp-2018-318956}}, doi = {{10.1136/jnnp-2018-318956}}, volume = {{90}}, year = {{2019}}, }